Figure 1From: Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer Progression-free and overall survival by study arm (a,c) and by serum assay classifier (b,d). Back to article page